Bris­tol My­er­s' TYK2 drug bombs ul­cer­a­tive col­i­tis test, but hopes are still high with pso­ri­a­sis fil­ing on deck

Bris­tol My­ers Squibb’s deu­cravac­i­tinib, seek­ing to be­come the first TYK2 drug ap­proved, flopped a key Phase II test in ul­cer­a­tive col­i­tis, fail­ing to spur clin­i­cal re­mis­sion at three months and miss­ing key sec­ondary end­points at an in­ter­im check-in, the drug gi­ant ad­mit­ted Thurs­day.

De­tails were slim in a press re­lease, but Bris­tol My­ers not­ed it still has plans to pur­sue deu­cravac­i­tinib in ul­cer­a­tive col­i­tis — an­oth­er Phase II test is cur­rent­ly on­go­ing — as well as a host of oth­er in­di­ca­tions for what it still sees as a $4 bil­lion-per-year peak sell­er by the end of the decade.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.